

FRIDAY JUNE 28, 2024

TIME	ABSTRACT NO	
<p>○ OPENING CEREMONY</p>		
	ROOM A	CONFERENCES <i>Chairs: Icro Maremmani (Pisa, Italy, EU)</i>
17:15 17:30	CF-0	LUIS PATRICIO (Lisbon, Portugal, EU) - Conference opening
17:30 18:00	CF-1	MARK PARRINO (New York, NY, USA) - Overdosis with opioid treatment/ long acting politics
18:00 19:00	CF-2	NICHOLAS LINTZERIS (Sydney, NW, Australia) - Patient-Reported Outcomes of Treatment of Opioid Dependence with Weekly and Monthly Subcutaneous Depot
19:00 20:00	CF-3	MICHAEL KRAUSZ (Vancouver, BC, Canada) - Opioid Overdose Crisis in Northern America and Its Potential Impact on Europe.
<p>○ WELCOME COCKTAIL AND CHIMERA AWARD 2024</p>		
20:00		THE ALESSANDRO TAGLIAMONTE AWARD <i>Chairs: Icro Maremmani (Pisa, Italy, EU), Marc Reisinger (Brussels, Belgium, EU) and Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
		CHIMERA award 2024
		TO BE AWARDED: FRANCINA FONSECA (Barcelona, Spain, EU)
		CELIA FRANCO (Coimbra, Portugal, EU)
		ALBRECHT ULMER (Stuttgart, Germany, EU)
		CAREER AWARD: NICHOLAS LINTZERIS (Sydney, NW, Australia)
		FRIEND OF THE FIELD AWARD: MARIO MICCOLI (Pisa, Italy, EU)
		 <p>CHIMERA AWARD European Opiate Addiction Treatment Association Award <i>"The Alessandro Tagliamonte Award"</i></p>   <p>"Dedicated to all those who dream of a better world for drug addicts"</p>
		 <p>PISA ROVAI SCHOLARS AWARD School of Addiction Medicine <i>"The Luca Rovai Award"</i></p>  <p>"Dedicated to all those who dream of a better world for drug addicts"</p>

Best poster Rovai Scholars award

SATURDAY JUNE 29, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
8:00 9:30	ROOM A	IP01 - EUROPAD INVITED PRESENTATIONS <i>Chair: Name Surname (City, Country, Federation)</i>
8:00 8:30	IP01-1	HEIKE ZURHOLD (Hamburg, Germany, EU) - OAT Attitudes in German Drug Scenes: Comparison of OAT Experienced with OAT Naive Opioid Dependent Persons.
8:30 9:00	IP01-2	ALBRECHT ULMER (Stuttgart, Germany) - Paradigm Shift (Opioid relevance) in the Treatment of Alcohol Addicts.
9:00 9:30	IP01-3	OMRI SINAI (Jerusalem, Israel) - Case Series: Prospective Study: Efficacy of Pregabalin in Managing Opioid Withdrawal Syndrome with and without Dual Diagnosis Disorder.
8:00 9:30	ROOM B	IP02 - EUROPAD INVITED PRESENTATIONS <i>Chair: Name Surname (City, Country, Federation)</i>
8:00 8:30	IP02-1	SIMON OLIVIER (Lausanne, Switzerland) - Opioid Agonist Treatment in Switzerland: Quo Vadis?
8:30 9:00	IP02-2	DIPALI RINKER (Houston, TX, USA) - Racial Differences in the Association between Income and Knowledge of Opioid Misuse and Opioid Misusing Behaviors among People Living with Hiv in an Outpatient Infectious Disease Clinic.
9:00 9:30	IP03-3	NUSA SEGREC (Ljubljana, Slovenia, EU) - The Role of Medication Assisted Treatment in Opioid Addiction and Functional Recovery of Patients.
○ CONFERENCE		
	ROOM A	CONFERENCES <i>Chair: Name Surname (City, Country, Federation)</i>
9:30 10:00	CF-4	MARC REISINGER (Brussels, Belgium, EU) - Is It Possible to Detoxify Patients with a Long-Acting Opioid Medication?
10:00 10:30	CF-5	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Experience with Buprenorphine S.C. Depot Injection and Induction with Microdosing in Slovenia.

SATURDAY JUNE 29, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
10:30 12:00	ROOM A	S01 -BUPRENORPHINE DEPOT EXPERIENCES <i>Chair: Nicholas Lintzeris (Sydney, NW, Australia)</i>
10:30 11:00	S01-1	MARC AURIACOMBE (Bordeaux, France, EU) - A Prospective Observational Study in Naturalistic Settings to Describe Long-Acting Injectable Buprenorphine Introduction in France: The Obap Cohort Study.
11:00 11:30	S01-2	ALICE DESCHENAU (Villejuif, France, EU) - Treatment of Opioid Dependence with Long-Acting Buprenorphine in Real Life in France: Retention on Treatment at 6 Months, Opale 2 Study.
11:30 12:00	S01-3	CABÉ JULIEN (Clermont-Ferrand, France, EU) - Should the Prescription of Extended-Release Buprenorphine Be Reserved for a Specific Patient Profile? Answers from a Real-Life French Cohort.
10:30 12:00	ROOM B	S04 - PSYCHOTHERAPY IN OPIOID ADDICTION TREATMENT <i>Chair: Alexander Kantchelov (Sofia, Bulgaria, EU)</i>
10:30 11:00	S02-0	TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - Tbc.
11:00 11:30	S02-2	ALEXANDER BELCHEV (Luton, Bedfordshire, UK) - Optimal Strategies for Ballancing Treatment Targets with Clients' Goals in the Context of Disruptive Affect.
11:30 12:00	S02-3	RIK BES (Alkmaar, Netherlands, EU) - The Forest and the Trees: In Search of Effective Psychotherapists.
○ CONFERENCES		
	ROOM A	CONFERENCES <i>Chair: Name Surname (City, Country, Federation)</i>
12:00 13:00	CF-6	MAURICE DEMATTEIS (Grenoble, France, EU) - Treating pain in OUD patients
13:00 14:00	CF-7	ANGELO G. I. MAREMMANI (Pisa, Italy, EU) - Chronic Psychoses and Opioid Medications.
LUNCH ON YOUR OWN		

SATURDAY JUNE 29, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
15:30 17:00	ROOM A	S03 - OPIOID AGONIST TREATMENT (OAT) IN EUROPEAN PRISONS: TREATMENT NEEDS, ALTERNATIVE APPROACHES AND IMPLEMENTATION <i>Chairs: Fadi Meroueh (Montpellier, France, EU) Filipa Alves da Costa (WHO Regional Office for Europe, City, Country)</i>
15:30 15:50	S03-1	HEINO STOVER (Frankfurt, Germany, EU) - OAT in Prison: An Introductory Reflection on the Needs, Benefits and Approaches to OAT in Prison.
15:50 16:10	S03-2	LINDA MONTANARI (Lisbon, Portugal, EU) - What Is the Evidence-Base Driving Policy Decisions in Europe? Overview of Latest Available Data on OAT Provision, Coverage and Approaches in European Countries. Data Gaps.
16:10 16:30	S03-3	ANJA BUSSE (Vienna, Austria) - International Standards and Guidelines for the Provision of OAT in Prison.
16:30 16:40	S03-4.1	To Be Confirmed - Case Studies: The Portuguese Approach to OAT in Prison (Focus on Methadone).
16:40 16:50	S03-4.2	FADI MEROUEH (Montpellier, France, EU) - Case Studies: The French Approach to OAT in Prison (Focus on Long-Acting Buprenorphine).
16:50 17:00	S03-4.3	NIJOLE GOSTAUTAITE (Montpellier, France, EU) - Case Studies: The Lithuanian Approach to OAT in Prison (Focus on Combined Buprenorphine/Naloxone).
15:30 17:00	ROOM B	S04 - IMPACT OF COVID 19 PANDEMIC ON SUBSTANCE USE AND CONSEQUENCES: LESSONS LEARNED <i>Chair: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
15:30 16:00	S04-1	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Hospital Admissions for Alcohol, Cannabinoids, Benzodiazepines and Narcotics-Related Intoxications among Children, Adolescents and Young Adults in Slovenia in the Period before and after the Start of the Covid-19 Pandemic.
16:00 16:30	S04-2	TBC (Ljubljana, Slovenia, EU) - Retrospective Cohort Study on Heroin Addicts in Opioid Agonist Treatment Programme in the 22 Years Period: Causes of Death before and after Covid 19 Pandemic Start.
16:30 17:00	S04-3	TBC (Ljubljana, Slovenia, EU) - Mild Cognitive Impairment and Dementia among Heroin Addicts in Outpatient Opioid Agonist Treatment.
○ CONFERENCES		
	ROOM A	CONFERENCES <i>Chair: Name Surname (City, Country, Federation)</i>
17:00 18:00	CF-8	MARTA TORRENS (Barcelona, Spain, EU) - Depression and Anxiety in Dual Disorders Heroin Addicts
18:00 19:00	CF-9	MARC AURIACOMBE (Bordeaux, France, EU) - Why Is Craving So Important? What to Do About It?
20:00		SOCIAL DINNER*
		* Tickets are available for all delegates

SUNDAY JUNE 30, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
8:30 10:00	ROOM A	IP03 - EUROPAD INVITED PRESENTATIONS <i>Chair: Name Surname (City, Country, Federation)</i>
8:30 9:00	IP03-1	BRIDIN MURNION (Sydney, Australia, AUS) - Barriers and Facilitators to Physical Health Care Experienced by People with Opioid Dependence.
9:00 9:30	IP03-2	CÉU MATEUS (Lancaster, UK) - Experiences of and Outcomes for Blackpool Adults Who Are Treated with Buprenorphine Prolonged-Release Injection (Buvidal) Opioid Substitution Therapy.
9:30 10:00	IP03-3	FELIPE LOZANO-ROJAS (Athens, GA, USA) - The Effect of Medical Cannabis Laws on Use of Pain Medications among Commercially Insured Patients in the United States.
8:30 10:00	ROOM B	IP04 - EUROPAD INVITED PRESENTATIONS <i>Chair: Name Surname (City, Country, Federation)</i>
8:30 9:00	IP04-1	LILJANA IGNJATOVA (Skopje, North Macedonia) - Predictors of Outcome in Methadone Maintenance Treatment.
9:00 9:30	IP04-2	LINDA HURLEY (Cranston, RI, USA) - Providing Methadone and Buprenorphine from a Mobile Unit.
9:30 10:00	IP04-3	SOFIA GOLBREICH (Bat Yam, Israel, ISR) - Case Series: Prospective Study: Efficacy of Pregabalin in Managing Opioid Withdrawal Syndrome with and without Dual Diagnosis Disorder.
○ CONFERENCES		
	ROOM A	CONFERENCE 6 <i>Chair: Name Surname (City, Country, Federation)</i>
10:00- 11:00	CF-10	GABRIELE FISCHER (Vienna, Austria, EU) - Medical Standards and Human Rights for Diagnosis and Treatment of Opioid Dependence in Prison.
11:00 12:00	CF-11	LORENZO SOMAINI (Biella, Italy, EU) - What Is Changing with Opioid Long-Acting Medications?

SUNDAY JUNE 30, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
11:00-12:30	ROOM A	IP05 - EUROPAD INVITED PRESENTATIONS <i>Chair: Name Surname (City, Country, Federation)</i>
11:00-11:30	IP05-1	FRANCINA FONSECA (Barcelona, Spain, EU) - Value Stream Mapping Methodology for Improving Access to Hepatitis C Treatment in Opioid Addiction.
11:30-12:00	IP05-2	DESIREE EIDE (Oslo, Norway) - Norway's First Heroin-Assisted Treatment Clinics: Initial Impact of the Intervention.
12:00-12:30	IP05-3	FILIPPO DELLA ROCCA (La Spezia, Italy, EU) - Exploring the Depressive Syndrome of Heroin Use Disorder Patients. Relationships between Worthlessness/Being Trapped, Deficit Reward and Post-Withdrawal Syndromes.
11:00-12:30	ROOM B	IP06 - EUROPAD INVITED PRESENTATIONS <i>Chair: Name Surname (City, Country, Federation)</i>
11:00-11:30	IP06-1	RAMINTA DANIULAITYTE (Phoenix, AZ, USA) - "Fentanyl Made Heroin Not Work Anymore": Exploring Transitions from Heroin to Illicitly Manufactured Fentanyl Use in Arizona, USA.
11:30-12:00	IP06-2	JONATHAN DALE CHICK (North Berwick, Scotland, UK) - Prescribing Psychiatric Medications in Alcohol Use Disorders and Other Addictions: Risks and Avoiding Risk.
12:00-12:30	IP06-3	DAVID BRADFORD (Athens, GA, USA) - The Effect of a Large Prescription Opioid Diversion Event on Opioid Mortality in the U.S.
○ CONFERENCE		
12:30-13:30	ROOM A	CONFERENCE 7 <i>Chair: Marta Torrens (Barcelona, Spain, EU)</i>
12:30-13:00	CF-12	ICRO MAREMMANI (Pisa, Italy, EU) - Methadone anticraving dosages and opioid debt in OUD patients
13:00-14:00	CF-13	EINAT PELES (Tel Aviv, Israel) - Nutrition, Eating Habits and Weight Reduction Intervention among Opioid Maintenance Treatment Patients.
14:30-15:00	CLOSING REMARKS	ICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Bucarest (Romania) in May 2026

○ POSTERSESSION

P01	Amanda J. ABRAHAM and Felipe LOZANO-ROJAS (Athens, GA, USA) - Introduction of Medicare Coverage of Services Delivered in Opioid Treatment Programs in the United States.
P02	Roberto CICCOCIOOPPO, Luisa DE VIVO, Laura SOVERCHIA, Massimo UBALDI, Veronica LUNERTI and Nazzareno CANNELLA (Camerino, Italy, EU) - Long-Access Heroin Self-Administration Induces Region Specific Reduction of Grey Matter Volume and Microglia Reactivity in Nih Heterogeneous Stock Rats.
P03	Sara DE CARLO, Hela MRIZAK, Andrea DELLA VALLE, Veronica LUNERTI, Alessandra MAMMONE, Manthoula KYRATZI, Antonio LACORTE, Adana KESHISHIAN, Min LI, Esi DOMI, Massimo UBALDI, Roberto CICCOCIOOPPO and Nazzareno CANNELLA (Camerino, Italy, EU) - Predicting Individual Treatment Response in Alcohol Use Disorder: A Reverse Translational Proof-of-Concept Study.
P04	Simone DE PERSIS, Marta MATRONE, Andrea ROMANO, Giulia MOLTONI and Paola MOTTA (Rieti, Italy, EU) - Alterations in Resting-State Functional Connectivity of the Salience Network in Patients with Schizophrenia with and without Cannabis Use Disorder Comorbidity.
P05	Miguel DIAZ and Charlotta TEGNESTEDT (Huddinge, Sweden, EU) - The Spectrum of Addiction: Biological, Behavioral, and Therapeutic Dimensions.
P06	Silvia DIAZ-FERNANDEZ and Juan J. FERNANDEZ-MIRANDA (Gijón, Spain, EU) - Sociodemographic, Clinical and Treatment Differences by Gender in Addictive and Psychiatric Disorders Comorbidity.
P07	Juan J. FERNANDEZ-MIRANDA and Silvia DIAZ-FERNANDEZ (Gijón, Spain, EU) - Dual Diagnoses in Mental Health or Addiction Treatment Settings in Spain: Clinical Differences.
P08	Vahe HEBOYAN, Katherine HATCHER and Gianluca DE LEO (Augusta, United States of America, USA) - Factors and Barriers Associated with Oud Treatment Seeking Behavior among Adults in the United States: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions – Iii.
P09	Vahe HEBOYAN, Katherine HATCHER and Gianluca DE LEO (Augusta, United States of America, USA) - Prevalence and Correlates of Opioid Use in the United States: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions – III.
P10	Ali KHERADMAND, Helya HELALI, Faraj TABEIE and Shiva ILIAIEE (Tehran, Iran,) - The Effect of Photobiomodulation on Reducing Anxiety, Depression, and Opioid Craving in Patients with Methadone Maintenance Treatment.
P11	A. V. KHODZHAEV, M. KAMINSKAYA YU, S.I. OSIPCHIK, I.V. GRIGORIEVA and S.A. IGUMNOV (Minsk, Belarus) - Organisation of an Opioid Substitute Therapy Program in the Republic of Belarus.
P12	Beata KREMBUSZEWSKI, Emma ANDERSON-WHITE and Craig HENDERSON (Millbury, TX, USA) - Positive Psychology as a Protective Factor for Illicit Opioid Use in Individuals Receiving Methadone Treatment.
P13	Hongwu LI, Veronica LUNERTI, Qianwei SHEN, Federica BENVENUTI, Laura SOVERCHIA, Nazzareno CANNELLA and Roberto CICCOCIOOPPO (Camerino, Italy, EU) - Cebranopadol, a Novel Long-Acting Opioid Agonist with Low Abuse Liability, to Treat Opioid Use Disorder: Preclinical Evidence of Efficacy.
P14	Jan LIGON (Atlanta, GA, USA) - Usefulness of a Brief Educational Event to Challenge Provider Approaches with Families Affected by Substance Abuse.
P15	Michelle LOFWALL, Edward NUNES, Sharon WALSH, Genie BAILEY, Michael FROST, Natalie BUDILOVSKY-KELLEY, Elin BANKE NORDBECK and Fredrik TIBERG (Lexington, KY, USA) - Dosing to Effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder.
P16	Rosemarie MARTIN, Jennifer WOOD, Alyssa DACUNHA, Amelia BAILEY, Lauren PERRON, Steven BELENKO, Lynda STEIN and Damaris ROHSENOW (Providence, RI, USA) - Identifying Gaps in Connecting People on Probation to Community-Based Substance Use Services Using Action Planning and Goals among Justice-Provider Partnerships.
P17	Rosemarie MARTIN, Ryan CARPENTER, Ariel HOADLEY, Amelia BAILEY, Alyssa DACUNHA, Augustine KANG, Josiah RICH, Damaris ROHSENOW, Linda HURLEY and Jennifer CLARKE (Providence, RI, USA) - Providing Evidence-Based Addiction Treatment During Incarceration Decreases Overdose Deaths after Incarceration.
P18	Kaisa MISHINA, Jasmin LOSTEDT and Solja NIEMELÄ (Tutku, Finland, EU) - Perceived Discrimination among People Who Inject Opioids.
P19	Stefan PETERSON, Edward NUNES, Michelle LOFWALL, Sharon WALSH and Fredrik TIBERG (Lund, Sweden, EU) - Exploring Opioid Use Disorder Outcomes by Quantitative Urine Analysis: Post-Hoc Analysis of a Phase 3 Randomised Clinical Trial Comparing a Subcutaneous Buprenorphine Depot (Cam2038) and Sublingual Buprenorphine.
P20	Di QIN, Nazzareno CANNELLA, Laura SOVERCHIA, Massimo UBALDI and Roberto CICCOCIOOPPO (Camerino, Italy, EU) - Nih Heterogeneous Stock Rats Trained to Heroin Self-Administration Show Heterogeneous Response to the Anti-Addictive Effects of the Mop/Nop Agonist Cebranopadol.

P21	Anat SASON and Einat PELES (Tel-Aviv, Israel) - Patients' Anxiety Levels and Their Reactions Towards the Needed Changes of Policies in Methadone Maintenance Treatment Following the October 7th Events.
P22	Aneta SPASOVSKA TRAJUANOVSKA (Skopje, North Macedonia) - The Effectiveness of Escitalopram Use in the Treatment of Anxiety Conditions in Patients on Metadone Treatment.
P23	Massimo UBALDI, Hela MRIZAK, Veronica LUNERTI, Laura RULLO, Esi DOMI, Patrizia ROMUALDI, Roberto CICCOCIO PPO and Nazzeno CANNELLA (Camerino, Italy, EU) - Increased Mop Expression in the Ventral Tegmental Area Mediates Higher Heroin Self-Administration and Motivation Expressed by Marchigian Sardinian Alcohol Preferring Rats Compared to Non-Preferring Wistars.



PISA ROVAI SCHOLARS AWARD
"The Luca Rovai Award"
"Dedicated to all those who dream of a better world for drug addicts"

Rovai Scholars award, named after one of the founding member of PISA-School of Addiction Medicine Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Addiction Medicine and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

FORMER RECIPIENTS:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Marenmani (Pisa, Italy, EU). Poster presented at *New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives* Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R. V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen (Ann Arbor, MI, USA). Poster presented at *2° World Congress of the World Association on Dual Disorders (WADD)*, Florence, October 25-27 2018

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tripodi, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi (Pisa, Italy, EU). Poster presented at *Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders*, Pisa, Italy, EU, July, 8-9 2019

High therapeutic buprenorphine levels reduce i.v. fentanyl respiratory depression by M. G. Tocco, K. Wiest, M. H. Algera, L. Moss, M. van Velzen, G. J. Groeneveld, J. Heuberger, A. Dahan, F. Gray, S. Strafford, R. Dobbins (Milan, Italy, EU). Poster presented at *14th EUROPAD European Congress*, Grenoble, France, November 19-21, 2021

Early experience of buprenorphine long-acting injection in Finland. A retrospective cohort study by M. Partanen, T. Saarenpää, T. Prami, I. Iso-Mustajärvi, B. Ryder and K. Simojoki (Turku, Suomi, Finland, EU). Poster presented at *15th European Congress of EUROPAD*, Pisa, Italy, May 20-22, 2022

Alexithymia as a Risk Factor of Addictive Behavior by Sergey Igumnov and Lapanov Pavel (Minsk, Belarus - Gomel, Belarus). Poster presented at *WADD 7th World Congress*, Portoroz, Slovenia, April 28-30, 2023

